|
1
|
World Health Organization; International
Agency for Research on Cancer, . GLOBOCAN 2012. Stomach Cancer.
Estimated Incidence, Mortality and Prevalence Worldwide in 2012.
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspxAccessed:December
1–2014.
|
|
2
|
No authors listed: Schistosomes, liver
flukes, and Helicobacter pylori, . IARC Working Group on the
Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994.
IARC Monogr Eval Carcinog Risks Hum. 61:1–241. 1994.PubMed/NCBI
|
|
3
|
Macdonald JS: Clinical overview: Adjuvant
therapy of gastrointestinal cancer. Cancer Chemother Pharmacol. 54
(Suppl 1):S4–S11. 2004.PubMed/NCBI
|
|
4
|
Alberts DS, Garcia D and Mason-Liddil N:
Cisplatin in advanced cancer of the cervix: An update. Semin Oncol.
18 (1 Suppl 3):11–24. 1991.PubMed/NCBI
|
|
5
|
Zhou F, Yu Z, Jiang T, et al: Genetic
polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of
platinum-based chemotherapy in advanced non-small cell lung cancer
(NSCLC) patients. Swiss Med Wkly. 141:w132752011.PubMed/NCBI
|
|
6
|
Xu J, Ma J, Zong HT, et al:
Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome
of gastric cancer patients with platinum-based chemotherapy: A
systematic review and meta-analysis. Genet Mol Res. 13:1438–1446.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang X, Jiang LP, Yin Y and Wang YD:
XRCC1 and XPD genetic polymorphisms and clinical outcomes of
gastric cancer patients treated with oxaliplatin-based
chemotherapy: A meta-analysis. Tumour Biol. 35:5637–5645. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu ZM, Luo TH, Nie MM, et al: Influence of
ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric
cancer treated with FOLFOX-based chemotherapy. Tumour Biol.
35:2941–2948. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang X, Zhu H, Wu X, et al: A genetic
polymorphism in TOX3 is associated with survival of gastric cancer
in a Chinese population. PLoS One. 8:e721862013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, Liu Z, Liu H, et al: ERCC1 and ERCC2
variants predict survival in gastric cancer patients. PLoS One.
8:e719942013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hasmats J, Kupershmidt I, Rodríguez-Antona
C, et al: Identification of candidate SNPs for drug induced
toxicity from differentially expressed genes in associated tissues.
Gene. 506:62–68. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marsh S, McLeod H, Dolan E, et al:
Platinum pathway. Pharmacogenet Genomics. 19:563–564. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Deans AJ and West SC: DNA interstrand
crosslink repair and cancer. Nat Rev Cancer. 11:467–480. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Enoiu M, Jiricny J and Schärer OD: Repair
of cisplatin-induced DNA interstrand crosslinks by a
replication-independent pathway involving transcription-coupled
repair and translesion synthesis. Nucleic Acids Res. 40:8953–8964.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sharma S and Canman CE: REV1 and DNA
polymerase zeta in DNA interstrand crosslink repair. Environ Mol
Mutagen. 53:725–740. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li X and Heyer WD: Homologous
recombination in DNA repair and DNA damage tolerance. Cell Res.
18:99–113. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Costa RM, Chiganças V, Galhardo Rda S, et
al: The eukaryotic nucleotide excision repair pathway. Biochimie.
85:1083–1099. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miller AB, Hoogstraten B, Staquet M and
Winkler A: Reporting results of cancer treatment. Cancer.
47:207–214. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edge SB, Byrd DR, Compton CC, et al:
StomachAJCC Cancer Staging Manual. 7th. Springer; New York, NY: pp.
1202010
|
|
20
|
Zhou J, Liu ZY, Li CB, et al: Genetic
polymorphisms of DNA repair pathways influence the response to
chemotherapy and overall survival of gastric cancer. Tumour Biol.
36:3017–3023. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Booton R, Ward T, Heighway J, et al:
Xeroderma pigmentosum group D haplotype predicts for response,
survival, and toxicity after platinum-based chemotherapy in
advanced nonsmall cell lung cancer. Cancer. 106:2421–2427. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chu H, Gu D, Xu M, et al: A genetic
variant in ERCC2 is associated with gastric cancer prognosis in a
Chinese population. Mutagenesis. 28:441–446. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li J, Zuo X, Lv X, et al: Association of
DNA repair gene polymorphisms with response to chemotherapy and
prognosis of gastric cancer in a Chinese population. Tumour Biol.
35:7569–7574. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lu ZM, Luo TH, Nie MM, et al: Influence of
ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric
cancer treated with FOLFOX-based chemotherapy. Tumour Biol.
35:2941–2948. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Caronia D, Patiño-García A, Milne RL, et
al: Common variations in ERCC2 are associated with response to
cisplatin chemotherapy and clinical outcome in osteosarcoma
patients. Pharmacogenomics J. 9:347–353. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Spitz MR, Wu X, Wang Y, et al: Modulation
of nucleotide excision repair capacity by XPD polymorphisms in lung
cancer patients. Cancer Res. 61:1354–1357. 2001.PubMed/NCBI
|
